The results of their mouse models study were published in the Journal of Virology.
This H1N1 flu vaccine differs from the current influenza vaccine because it does not require experts to guess which strain will be dominant each season, meaning manufacturers could create this vaccine year-round.
“What we have developed is a vaccine that protects against multiple different strains of H1N1 virus at once, so we might be able to one day replace the current standard of care with this more broadly cross-protective vaccine,” said Ted Ross, PhD, director of UGA’s Center for Vaccines and Immunology.
More articles on vaccines:
Key to optimizing the new pertussis vaccine might be going back to the old one
5 things to know about China’s vaccine scandal
Zika, HPV, flu: 5 recent stories on vaccines
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
